Trial Profile
Lenalidomide for the Treatment of CLL Patients With High-Risk Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 08 Jan 2011 New trial record